Clinical Trial Update: Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating denosumab for prevention of bone loss in non-menopausal women with anorexia nervosa; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anorexia Nervosa

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Anorexia Nervosa | Phase 3 | Status: TERMINATED